NCT05930782View on ClinicalTrials.gov

Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

December 6, 2023

Study Completion Date

January 3, 2024

Conditions
Malaria
Interventions
DRUG

Piperaquine Tetraphosphate uncoated tablets

Piperaquine tetraphosphate hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water

DRUG

Piperaquine Tetraphosphate dispersible granules

Piperaquine tetraphosphate dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally

Trial Locations (1)

Unknown

Ifakara Health Institute (IHI), Bagamoyo Research and Training Centre (BRTC), Bagamoyo

All Listed Sponsors
lead

Medicines for Malaria Venture

OTHER